Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2003-03-05
2010-10-19
Chang, Celia (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S253070, C514S254020, C514S254060, C514S312000, C514S320000, C514S367000, C514S375000, C514S394000, C544S363000, C544S368000, C544S373000, C546S158000, C546S198000, C546S199000, C546S201000
Reexamination Certificate
active
07816376
ABSTRACT:
The invention relates to compounds of the formula (I) and pharmaceutically usable derivatives, salts, solvates and stereoisomers and mixtures thereof, in which X, Y, Z, R1, R3, R4, R8, p, k, E, G, Z and Q are as defined in claim1, which are employed as excitatory amino acid antagonists for combating neurodegenerative diseases, including cerebrovascular diseases, epilepsy, schizophrenia, Alzheimer's, Parkinson's or Huntington's disease, cerebral ischaemia, infarction or psychoses.
REFERENCES:
patent: 4567187 (1986-01-01), Banno et al.
patent: 5036088 (1991-07-01), Kitaura et al.
patent: 5086062 (1992-02-01), Ando et al.
patent: 5698553 (1997-12-01), Prucher et al.
patent: 7435744 (2008-10-01), Domany et al.
patent: 2004/0157886 (2004-08-01), Domany et al.
patent: 0249407 (1987-12-01), None
patent: 0360566 (1990-03-01), None
patent: 0385664 (1990-09-01), None
patent: 0709384 (1996-05-01), None
patent: WO 0192239 (2001-12-01), None
patent: WO 0194321 (2001-12-01), None
patent: WO03/010159 (2003-02-01), None
Chemcasts 2040186577 (2007).
Rubini et al. “synthesis of isosteric . . . ” Tetrahedron v.42, p. 6039-6045 (1986).
Piao et al. “synthesis of 3,4- . . . ” CA 132:107929 (1999).
Piao et al. “synthesis and positive inotropic . . . ” CA 132:117316 91999).
Seddon “Pseudopolymorph . . . ” Crystal growtyh and design 4(6) p. 1087 (2004) (internet print out).
Braga et al. “Making crystal from crystals . . . ” Chem. Comm p. 3635-3645 (2005).
Domany et al. “Preparation of 2-piperidin . . . ” CA 138:153539 (2003).
Pruecher et al. “Preparation of benzylpiperidine . . . ” CA 125:58339 (1996).
Banno et al. “Preparation of piperazinylalkyl . . . ” CA 137:216963 (2002).
Masui et al. “Preparation of piperidine . . . ” CA 146:100694 (2006).
Berge “pharmaceutical salts” J. Pharm. Sci. v.66(10, p. 1-19 (1977).
Schadt et al. “preparation of . . . ” CA 139:246018 (2003).
Schadt et al. “Preparation of aminoalkanoylamino . . . ” CA 139:246018 (2003).
Shanklin, J et al.: “Diarylmethyl-Aryloxymethylpiperidine Derivatives and Structurally Related Compounds” J Med Chem. vol. 34, No. 10, 1991 pp. 3011-3022.
Etsuo Ohshima et al.: Dibenzoxepine Derivatives As Antiallergic Agents: J Med Chem, vol. 36. No. 3, 1993 pp. 417-420.
Leibrock Joachim
Pruecher Helmut
Schadt Oliver
Seyfried Christoph
Chang Celia
Merck Patent GmbH
Miller, White, Zelano & Branigan, P.C.
LandOfFree
Cyclic amides does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cyclic amides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cyclic amides will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4226379